000126390 001__ 126390
000126390 005__ 20240228135024.0
000126390 0247_ $$2doi$$a10.1016/S1470-2045(14)70442-5
000126390 0247_ $$2pmid$$apmid:25439696
000126390 0247_ $$2ISSN$$a1470-2045
000126390 0247_ $$2ISSN$$a1474-5488
000126390 0247_ $$2altmetric$$aaltmetric:2812302
000126390 037__ $$aDKFZ-2017-02419
000126390 041__ $$aeng
000126390 082__ $$a610
000126390 1001_ $$aRajkumar, S Vincent$$b0
000126390 245__ $$aInternational Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
000126390 260__ $$aLondon$$bThe Lancet Publ. Group$$c2014
000126390 3367_ $$2DRIVER$$aarticle
000126390 3367_ $$2DataCite$$aOutput Types/Journal article
000126390 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1505480924_23151
000126390 3367_ $$2BibTeX$$aARTICLE
000126390 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126390 3367_ $$00$$2EndNote$$aJournal Article
000126390 520__ $$aThis International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.
000126390 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000126390 588__ $$aDataset connected to CrossRef, PubMed,
000126390 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000126390 7001_ $$aDimopoulos, Meletios A$$b1
000126390 7001_ $$aPalumbo, Antonio$$b2
000126390 7001_ $$aBlade, Joan$$b3
000126390 7001_ $$aMerlini, Giampaolo$$b4
000126390 7001_ $$aMateos, María-Victoria$$b5
000126390 7001_ $$aKumar, Shaji$$b6
000126390 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b7$$udkfz
000126390 7001_ $$aKastritis, Efstathios$$b8
000126390 7001_ $$aRichardson, Paul$$b9
000126390 7001_ $$aLandgren, Ola$$b10
000126390 7001_ $$aPaiva, Bruno$$b11
000126390 7001_ $$aDispenzieri, Angela$$b12
000126390 7001_ $$aWeiss, Brendan$$b13
000126390 7001_ $$aLeLeu, Xavier$$b14
000126390 7001_ $$aZweegman, Sonja$$b15
000126390 7001_ $$aLonial, Sagar$$b16
000126390 7001_ $$aRosinol, Laura$$b17
000126390 7001_ $$aZamagni, Elena$$b18
000126390 7001_ $$aJagannath, Sundar$$b19
000126390 7001_ $$aSezer, Orhan$$b20
000126390 7001_ $$aKristinsson, Sigurdur Y$$b21
000126390 7001_ $$aCaers, Jo$$b22
000126390 7001_ $$aUsmani, Saad Z$$b23
000126390 7001_ $$aLahuerta, Juan José$$b24
000126390 7001_ $$aJohnsen, Hans Erik$$b25
000126390 7001_ $$aBeksac, Meral$$b26
000126390 7001_ $$aCavo, Michele$$b27
000126390 7001_ $$aGoldschmidt, Hartmut$$b28
000126390 7001_ $$aTerpos, Evangelos$$b29
000126390 7001_ $$aKyle, Robert A$$b30
000126390 7001_ $$aAnderson, Kenneth C$$b31
000126390 7001_ $$aDurie, Brian G M$$b32
000126390 7001_ $$aMiguel, Jesus F San$$b33
000126390 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(14)70442-5$$gVol. 15, no. 12, p. e538 - e548$$n12$$pe538 - e548$$tThe @lancet <London> / Oncology$$v15$$x1470-2045$$y2014
000126390 909CO $$ooai:inrepo02.dkfz.de:126390$$pVDB
000126390 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126390 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000126390 9141_ $$y2014
000126390 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126390 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126390 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126390 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2015
000126390 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000126390 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000126390 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126390 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126390 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126390 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126390 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bLANCET ONCOL : 2015
000126390 9201_ $$0I:(DE-He78)E013-20160331$$kE013$$lHämatoonkologische Bildgebung$$x0
000126390 980__ $$ajournal
000126390 980__ $$aVDB
000126390 980__ $$aI:(DE-He78)E013-20160331
000126390 980__ $$aUNRESTRICTED